Domov › Mielodisplastični sindromi › Washington › Seattle
Klinične študije za Mielodisplastični sindromi v Seattle, WA
21 študij za Mielodisplastični sindromi išče udeležence na lokacijah v Seattle in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Swedish Medical Center-First Hill, Seattle
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Vključevanje udeležencevFaza 1
- Fred Hutchinson Cancer Center, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Vključevanje udeležencevFaza 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Vključevanje udeležencevFaza 1/2
- University of Washington, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Vključevanje udeležencevFaza 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Vključevanje udeležencevFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
Vključevanje udeležencevOpazovalna študija
- Fred Hutchinson, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Vključevanje udeležencevFaza 1/2
- Seattle Children's Hospital, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Vključevanje udeležencevFaza 2
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Vključevanje udeležencevFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Vključevanje udeležencevFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Vključevanje udeležencevFaza 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Vključevanje udeležencevFaza 1/2Vabljeni zdravi prostovoljci
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Vključevanje udeležencevFaza 2/3
- Seattle Cancer Care Alliance, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Vključevanje udeležencevFaza 1/2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Vključevanje udeležencevFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Vključevanje udeležencevFaza 2
- Fred Hutchinson Cancer Research Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Vključevanje udeležencevFaza 1
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Vključevanje udeležencevFaza 1
- Fred Hutchinson Cancer Center, Seattle
Študije za Mielodisplastični sindromi v drugih mestih
- Houston, TX43 študij
- Baldwin Park, CA26 študij
- New York City, NY21 študij
- Washington, DC20 študij
- Boston, MA19 študij
- Tampa, FL19 študij
- Miami, FL17 študij
- Columbus, OH14 študij
- Durham, NC14 študij
- Chicago, IL13 študij
- Atlanta, GA13 študij
- St. Louis, MO13 študij
Druge študije v Seattle
- Nemalicelični pljučni rak53 študij
- Rak (vse vrste)49 študij
- Rak prostate42 študij
- Akutna mieločna levkemija40 študij
- Rak dojke39 študij
- Metastatski rak39 študij
- Kolorektalni rak34 študij
- Rak pljuč33 študij
- Rak jajčnikov30 študij
- Množni mielom22 študij
- Akutna limfoblastna levkemija21 študij
- Rak mehurja21 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.